Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. - Witte,L.; Hicklin,D.A.; Zhu,Z.; Pytowski,B.; Kotanides,H.; Rockwell,P.; Bohlen,P. (Cancer Metastasis Rev, 1998)